tert-butyl 4-methyl-4-(pyridin-4-ylmethyl)piperidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-methyl-4-(pyridin-4-ylmethyl)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-methyl-4-(4-pyridylmethyl)piperidine-1-carboxylate；Tert-butyl 4-methyl-4-(pyridin-4-ylmethyl)piperidine-1-carboxylate
• 化学式: C₁₇H₂₆N₂O₂
• 分子量: 290.406
• InChiKey: FOZXDVDPENDXMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-methyl-4-(pyridin-4-ylmethyl)piperidine-1-carboxylate 在 溶剂黄146 作用下， 以80 %的产率得到tert-butyl 4-methyl-4-(piperidin-4-ylmethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO

  摘要：

  Provided herein are compounds that target KRas and are thus useful in the treatment of cancer.

  公开号：

  US20240287101A1
• 作为产物：
  描述：

  1-N-Boc-4-甲基羟甲基哌啶 在 三(三甲基硅基)硅烷 、 [Ir(dF(CF₃)ppy)₂(dtbbpy)](PF₆) 、 NiCl₂(4,4'-di-tert-butyl-2,2′-bipyridine) 、 sodium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 乙二醇二甲醚 为溶剂， 反应 16.5h， 生成 tert-butyl 4-methyl-4-(pyridin-4-ylmethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO

  摘要：

  Provided herein are compounds that target KRas and are thus useful in the treatment of cancer.

  公开号：

  US20240287101A1

文献信息

• [EN] HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS D'HOMOBISPYPÉRIDINYLE EN TANT QU'AGONISTES DES OXYSTÉROLS BÊTA, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2017095758A1

  公开（公告）日：2017-06-08

  In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R1, R2, R3, L, R4, X, Z, Li, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver Χ-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  在其多种实施方式中，本发明提供了Formula (I)的某些取代双哌啶基化合物及其药学上可接受的盐，其中环A、环B、R1、R2、R3、L、R4、X、Z、Li、Q和R5如本文所定义。本发明的新化合物及包含其化合物的药学上可接受的组合物可用作肝Χ-β受体（LXRβ）激动剂，并可用于治疗或预防与之相关的病理。这些病理包括但不限于炎症性疾病和胆固醇和脂质代谢缺陷所特征的疾病，如阿尔茨海默病。
• Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10752587B2

  公开（公告）日：2020-08-25

  In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R1, R2, R3, L, R4, X, Z, Li, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  在其许多实施方案中，本发明提供了式(I)的某些取代的双哌啶基化合物：及其药学上可接受的盐，其中环A、环B、R1、R2、R3、L、R4、X、Z、Li、Q和R5如本文所定义。本发明的新型化合物以及包含其化合物的药学上可接受的组合物可用作肝 X-β 受体 (LXRβ) 激动剂，并可用于治疗或预防与之相关的病症。这些病症包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，如阿尔茨海默病。
• HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3383853A1

  公开（公告）日：2018-10-10
• HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR (LXR) BETA AGONISTS FOR TREATING E.G. ALZHEIMER'S DISEASE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3383853B1

  公开（公告）日：2020-11-04
• HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS AND THEIR USE
  申请人：Rudd Michael T.

  公开号：US20180354901A1

  公开（公告）日：2018-12-13

  In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R 1 , R 2 , R 3 , L, R 4 , X, Z, Li, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.